Roubaix Capital LLC Has $2.31 Million Stock Position in Cryoport, Inc. (NASDAQ:CYRX)

Posted by MarketBeat News on Oct 8th, 2023

Roubaix Capital LLC increased its holdings in Cryoport, Inc. (NASDAQ:CYRX – Free Report) by 44.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 133,701 shares of the company’s stock after purchasing an additional 40,906 shares during the quarter. Roubaix Capital LLC owned approximately 0.29% of Cryoport worth $2,306,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of CYRX. Captrust Financial Advisors raised its holdings in Cryoport by 308.3% during the 2nd quarter. Captrust Financial Advisors now owns 2,319 shares of the company’s stock worth $72,000 after purchasing an additional 1,751 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Cryoport by 54.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,484 shares of the company’s stock worth $60,000 after buying an additional 878 shares during the last quarter. FMR LLC lifted its holdings in Cryoport by 34.1% in the first quarter. FMR LLC now owns 2,935 shares of the company’s stock valued at $70,000 after buying an additional 747 shares during the period. State of Wyoming boosted its position in Cryoport by 42.7% during the fourth quarter. State of Wyoming now owns 3,026 shares of the company’s stock valued at $53,000 after acquiring an additional 905 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Cryoport by 276.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,961 shares of the company’s stock worth $96,000 after acquiring an additional 2,908 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Cryoport Stock Down 0.6 %

Shares of NASDAQ CYRX traded down $0.07 during trading on Friday, hitting $12.18. The stock had a trading volume of 544,007 shares, compared to its average volume of 676,241. The firm has a fifty day moving average of $13.82 and a two-hundred day moving average of $17.70. The company has a market capitalization of $595.36 million, a PE ratio of -12.56 and a beta of 1.24. The company has a debt-to-equity ratio of 0.78, a current ratio of 14.54 and a quick ratio of 13.82. Cryoport, Inc. has a 12 month low of $11.64 and a 12 month high of $29.98.

Want More Great Investing Ideas?

Cryoport (NASDAQ:CYRX – Get Free Report) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.17). Cryoport had a negative return on equity of 7.23% and a negative net margin of 16.07%. The firm had revenue of $57.02 million during the quarter, compared to the consensus estimate of $56.94 million. As a group, equities research analysts forecast that Cryoport, Inc. will post -1.11 EPS for the current fiscal year.

Insider Transactions at Cryoport

In other Cryoport news, insider Jerrell Shelton sold 26,875 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $14.27, for a total value of $383,506.25. Following the transaction, the insider now owns 632,424 shares of the company’s stock, valued at $9,024,690.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on CYRX shares. B. Riley dropped their price target on Cryoport from $30.00 to $22.00 in a research note on Thursday, July 13th. UBS Group downgraded Cryoport from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $28.00 to $17.00 in a report on Tuesday, July 18th. SVB Leerink cut Cryoport from an “outperform” rating to a “market perform” rating in a report on Thursday, July 13th. Morgan Stanley initiated coverage on shares of Cryoport in a research note on Thursday, August 17th. They set an “equal weight” rating and a $16.00 price target for the company. Finally, SVB Securities lowered shares of Cryoport from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $30.00 to $10.00 in a research note on Thursday, July 13th. Five investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.78.

Read Our Latest Stock Report on CYRX

Cryoport Company Profile

(Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Featured Articles

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryoport, Inc. (NASDAQ:CYRX – Free Report).

Receive News & Ratings for Cryoport Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.